Diversified End-markets & Strategic PartnershipsLumibird's exposure across defense, medical and industrial end markets and explicit strategic partnerships provide durable demand channels and access to large contracts. This diversification and partner-backed access reduce single-market cyclicality and support repeatable revenue streams.

Improved Profitability In 2025A clear margin inflection in 2025 — higher operating and net margins — suggests structural improvements (pricing, product mix, or cost control). If sustained, this supports durable earnings power and the ability to fund R&D and service investments without relying solely on revenue growth.

Manageable Leverage And Expanding Equity BaseModerate debt levels and growing equity give the company financial flexibility for capex, R&D and selective M&A. An expanded asset base and improving ROE in 2025 support scale-up potential while keeping balance-sheet risk at a manageable level versus peers.

Bears Say

Volatile Free Cash Flow And Weak Cash ConversionInconsistent operating and free cash flow — with prior negative FCF years and only ~30% conversion in 2025 — suggests working-capital swings or capex intensity. This reduces resilience, constrains reinvestment or debt reduction, and limits the durability of reported profits.

Decelerating Revenue Growth RecentlyTop-line growth has slowed to low-single-digit rates in 2024–2025 after earlier stronger expansion. Slower organic growth constrains leverage benefits from scale, limits margin expansion opportunities and increases reliance on product innovation or M&A to drive medium-term growth.

Margin Volatility And Data-quality NoteUneven margins historically and a flagged gross-profit reporting anomaly reduce confidence in underlying margin sustainability. This complicates forecasting and undermines the reliability of recent margin gains as a foundation for long-term profitability assumptions.

LBIRD FAQ

What was Lumibird SA’s price range in the past 12 months?

Lumibird SA lowest stock price was €8.14 and its highest was €24.50 in the past 12 months.

What is Lumibird SA’s market cap?

Lumibird SA’s market cap is €477.11M.

When is Lumibird SA’s upcoming earnings report date?

Lumibird SA’s upcoming earnings report date is Sep 29, 2026 which is in 196 days.

How were Lumibird SA’s earnings last quarter?

Lumibird SA released its earnings results on Mar 17, 2026. The company reported €0.4 earnings per share for the quarter, beating the consensus estimate of N/A by €0.4.

Is Lumibird SA overvalued?

According to Wall Street analysts Lumibird SA’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Lumibird SA pay dividends?

Lumibird SA does not currently pay dividends.

What is Lumibird SA’s EPS estimate?

Lumibird SA’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Lumibird SA have?

Lumibird SA has 22,466,883 shares outstanding.

What happened to Lumibird SA’s price movement after its last earnings report?

Lumibird SA reported an EPS of €0.4 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went up 0.505%.

Which hedge fund is a major shareholder of Lumibird SA?

Currently, no hedge funds are holding shares in FR:LBIRD

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

Lumibird SA

Lumibird SA designs, manufactures, and sells various lasers for the scientific, industrial, and medical applications worldwide. It operates in two divisions, Photonics and Medical. The Photonics division offers solid-state lasers, high power laser diodes, fiber lasers, fiber amplifiers and components, photonics solutions for time-of-flight lidar and range-finding, and doppler lidar systems for wind measurement. Its products are used in various applications, such as industrial and scientific, defense and space, and lidar sensors. The Medical division provides medical and ophthalmological solutions from diagnosis to laser treatment. The company was founded in 1970 and is headquartered in Lannion, France.